Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3
Company

Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3

CompanyDrug

Huadong Medicine’s ROR1 ADC HDM2005 Granted FDA Fast Track Designation — First Domestic ROR1 ADC to Achieve the Status

CompanyDrug

Micot’s First‑in‑Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial

Policy / Regulatory

NMPA Suspends Sales and Use of Pierre Fabre’s Encorafenib Capsules Over Unapproved Manufacturing Change

Policy / Regulatory

China’s NHSA Issues Guiding Opinions Establishing Unified Payment Management for Long‑Term Care Insurance (LTCI)

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%
Company

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

CompanyDrug

Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First‑Line Gastric Cancer

Others

Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT‑i

FDA Approves Revolution Medicines' Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer
CompanyDrug

FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer

NMPA Approves Novartis' Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer
CompanyDrug

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

FDA Approves J&J's IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab
CompanyDrug

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

FDA Approves BeOne's Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma
CompanyDrug

FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma